Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTHER
2023-508201-25-00Phase 2Authorised
- Sponsor
- Centre Eugène Marquis
- Start
- Mar 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of exl01, atezolizumab, bevacizumab, durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Centre Eugène Marquis. Primary endpoints: Objective response rate at week 12 by RECIST 1.1, Tumor response over time and 5 more. Planned start Mar 2025; status: authorised.
02
Drugs
exl01atezolizumabbevacizumabdurvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-508201-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508201-25-00.